Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 6:2020:3232950.
doi: 10.1155/2020/3232950. eCollection 2020.

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Chaofeng Li  1 , Tao Tang  1 , Wenyue Wang  1
Affiliations

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Chaofeng Li et al. Gastroenterol Res Pract. .

Abstract

Objective: To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC).

Methods: The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded.

Results: Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group.

Conclusion: The combination use could achieve good efficacy and prolong patients' PFS time; however, apatinib also reduced the patients' quality of life and enhanced the nutrition risk and adverse drug reactions.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or commercial conflict of interest.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
K-M curve for PFS time of the two groups of patients.
See this image and copyright information in PMC

References

    1. de Martel C., Forman D., Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterology Clinics of North America. 2013;42(2):219–240. doi: 10.1016/j.gtc.2013.01.003. - DOI - PubMed
    1. Hartgrink H. H., Jansen E. P. M., van Grieken N. C. T., van de Velde C. J. H. Gastric cancer. The Lancet. 2009;374(9688):477–490. doi: 10.1016/S0140-6736(09)60617-6. - DOI - PMC - PubMed
    1. Ferro A., Peleteiro B., Malvezzi M., et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. European Journal of Cancer. 2014;50(7):1330–1344. doi: 10.1016/j.ejca.2014.01.029. - DOI - PubMed
    1. Lordick F., Allum W., Carneiro F., et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treatment Reviews. 2014;40(6):692–700. doi: 10.1016/j.ctrv.2014.03.002. - DOI - PubMed
    1. Shen L., Shan Y.-S., Hu H.-M., et al. Management of gastric cancer in Asia: resource-stratified guidelines. The Lancet Oncology. 2013;14(12):e535–e547. doi: 10.1016/s1470-2045(13)70436-4. - DOI - PubMed